|GeoVax Labs, Inc.|
1900 Lake Park Drive
United States - Map
GeoVax Labs, Inc. operates as a biotechnology company. It focuses on developing vaccines that prevent and fight human immunodeficiency virus (HIV) infections that result in acquired immunodeficiency syndrome (AIDS). The companys vaccines under development address the clade B subtype of the HIV virus. Its vaccines incorporate two vaccine delivery components, including a recombinant DNA and recombinant poxvirus, known as modified vaccinia Ankara, which deliver genes that encode inactivated HIV derived proteins to the immune system. The companys clade B vaccines under development include DNA/MVA, a preventive vaccine that has completed Phase IIa clinical trial; and DNA-G/MVA, which is in Phase I clinical trial to prevent infection for use in uninfected humans exposed to the virus. Its clade B vaccine pipeline also comprises DNA/MVA, a therapeutic vaccine, which is in Phase I/II clinical trial. The company is also developing vaccines that address clade C subtype of the HIV virus, including DNA-G/MVA, a preventive vaccine that is in preclinical trial; and DNA-G/MVA, a therapeutic vaccine, which is in preclinical clinical trial for use in HIV infected humans. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
|Dr. Robert T. McNally Ph.D.,
Chief Exec. Officer, Pres and Director
|Dr. Harriet Latham Robinson Ph.D.,
Co-Founder, Chief Scientific Officer and Director
|Mr. Mark W. Reynolds CPA,
Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
|Mr. Donald G. Hildebrand ,
Founder, Chairman Emeritus and Consultant
|Dr. Arban Domi Ph.D.,
Director of Vector Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|